

235 Eugenie St. W., Suite 105D Windsor, ON N8X 2X7 Phone: 1-888-739-2718 | (519) 973-3040 Fax: 1-866-715-6337

March 1, 2019

RE: FDA WARNING LETTER TO CANARX

CanaRx has received a "warning letter" dated February 26, 2019, from the U.S. Food and Drug Administration. The FDA's description of CanaRx and its business model is incorrect. CanaRx is not an internet pharmacy nor a pharmacy itself of any kind. CanaRx does not contract with employers or plan sponsors to provide medications to employees. The CanaRx program does not involve new, experimental, unapproved or misbranded medications.

Rather, CanaRx works for individual American patients who wish to exercise their rights of personal importation, as permitted by law and by the FDA's own handbooks. CanaRx facilitates foreign physicians rewriting of the employee's valid U.S. prescription, and then supplies the employee with approved versions of FDA-approved drugs that have been sourced from Canada, the United Kingdom or Australia where they have undergone review from those countries' drug regulatory systems.

In the FDA's public statement yesterday, FDA Commissioner Scott Gottlieb, M.D., said "If an American consumer goes to Canada and walks into a brick-and-mortar Canadian pharmacy and buys a medicine, they're getting a high-quality drug because of Canada's first-class drug regulatory process." Commissioner Gottlieb is exactly right about that, and the same thing is true of Australia and the United Kingdom.

Every prescription that is dispensed through a CanaRx program is dispensed directly to the patient from a licensed, regulated, brick-and-mortar pharmacy in Canada, the United Kingdom, or Australia, and the patient can be sure that the medicine she receives is the medicine the doctor ordered.

CanaRx believes that the FDA is trying to prevent Americans from being injured by unregulated suppliers of counterfeit and other dangerous substances. CanaRx agrees with the FDA's goals and is part of the solution, not part of the problem. For over 15 years CanaRx has provided safe and affordable medications from Tier-One countries, and we believe our track record speaks for itself.

CanaRx will respond promptly, fairly and fully to the FDA. We intend to cooperate with the FDA in making sure that everyone has the facts straight in protecting the lives, health and the safety of each patient.

The CanaRx Group of Companies

FOR MORE INFORMATION, PLEASE EMAIL – <u>info@canarxgroup.com</u>

CanaRx Services Inc.

 \sim is dedicated to providing the highest quality, lowest cost, maintenance prescription medications available today \sim